Evidence map›Paper›PMID 40421600›Full record

ArticleRNA biology2025

The oncogenic microRNA miR-222 promotes human LINE-1 retrotransposition.

Tomer Friehmann, Yamama Abu Mohsen, Yehuda Schlesinger, Lucy Ghantous, Lika Gamaev, Chavah Landau Zenilman, Avi Harazi, Eithan Galun, Daniel S Goldenberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RNA biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tomer FriehmannThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0009-0006-1802-5478
Yamama Abu MohsenThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0009-0007-3832-5344
Yehuda SchlesingerThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0000-0002-6165-4433
Lucy GhantousThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0000-0003-1810-170X
Lika GamaevThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.
Chavah Landau ZenilmanThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.
Avi HaraziThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0009-0004-6903-4855
Eithan GalunThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0000-0002-6243-6702
Daniel S GoldenbergThe Goldyne Savad Institute of Gene and Cell Therapy, Hadassah University Medical Center (Hadassah Hebrew University Hospital), Jerusalem, Israel.ORCID 0000-0002-1618-4145

Funding

Modulating systemic pro-oncogenic effects of focal image-guided tumor ablationR01CA197081 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI AHMED, MUNEEB · 2016 to 2020
$2.4M
NCI NIH HHS R01 CA197081
6 · The paper itself

Abstract

The Long Interspersed Element-1 (LINE-1) contributes significantly to carcinogenesis and to tumour heterogeneity in many cancer types, including hepatocellular carcinoma (HCC), by its autonomous retrotransposition (RTP) and by its ability to retrotranspose some non-autonomous transposable elements. Previously, multiple proteins and a few microRNAs (miRs) were described as regulators of LINE-1 RTP. Here, we demonstrate that miR-222, which is oncogenic in HCC, promotes LINE-1 RTP in human HCC and some other cell lines

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLong Interspersed Nucleotide ElementsMicroRNAsCell Line, TumorGene Expression Regulation, NeoplasticHumansMicroRNAsMIR222, humanHCClet-7microRNAmiR-222retrotransposon

Identifiers

PMID40421600
PMCPMC12143727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.